Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
PCI Biotech: Invitation to fourth quarter and preliminary 2019 results presentation | ||
By: GlobeNewswire - 19 Feb 2020 | Back to overview list |
|
Oslo, Norway, 19 February 2020 - PCI Biotech invites to a presentation of the company's fourth quarter and preliminary 2019 results on Wednesday 26 February 2020 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 26 February, 08:30am – 09:30am CET (local time). The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CET) on 26 February 2020. For further information, please contact: Ronny Skuggedal, CFO About PCI Biotech Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. |
||
|
||
Copyright 2020 GlobeNewswire | Back to overview list |